Heidi Hagen

Ms. Heidi Hagen has extensive experience in operations management and commercializing innovative technologies for the last 30 years, including 20 years in the cell and gene therapy industry. Currently, Ms. Hagen is Chief Technology Officer of Sonoma Biotherapeutics, a privately held company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. She also serves on the Board of Directors for cell and gene therapy companies Vericel and Obsidian Therapeutics. For part of 2021, she served as interim CEO and sat on the board for Ziopharm Oncology for 2.5 years, a publicly traded company developing immune-oncology gene and cell therapies. She is also co-founder and former Chief Strategy Officer of Vineti, a software platform company for cell and gene therapy supply chain management. Formerly, she served as a Board member for Lykan Biosciences, the Global COO for SOTIO Biotech A.S. and the Senior Vice President of Operations for Dendreon. She began her career at Immunex Corporation and worked for ten years in a range of roles in drug development and operations management. Ms. Hagen has a BS in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.